SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gennex Laboratories Ltd (531739) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 531739 NSE: | Pharmaceuticals & Drugs | Small Cap

Gennex Lab Share Price

9.99 -0.12 (-1.19%)
As on 30-Apr'26 16:59

Gennex Laboratories Ltd (531739)

BSE: 531739 NSE:
Key Metrics
Market Cap
₹243 Cr.
P/E Ratio
16.59
Price to Book (P/B)
1.13
Price to Sales (P/S)
2.28
EV/EBITDA
10.59
Return on Capital Employed (ROCE)
10.25%
Current Price
₹10
Return on Equity (ROE)
8.16%
Return on Assets (ROA)
6.63%
Operating Profit Margin
10.9%
Net Profit Margin
14.84%
Gross Profit Margin
17.1%
Book Value per Share
₹8.9
Sales Growth (YoY)
41.59%
Sales Growth (3 Years)
15.61%
Operating Profit Growth (1 Year)
-16.91%
Operating Profit Growth (3 Years)
24.25%
Net Profit Growth (1 Year)
18.98%
52-Week Low / High
₹7 / 17
Net Profit Growth (3 Years)
52.95%
Dividend Yield
0.00%
Promoter Holding
23.63%
Pledged shares (%)
of Promoter's holding (%)
17.42%

Check Before You Invest

Q.1 Stock return of Gennex Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 4.3% based on the current price.
Q.1 Revenue growth of Gennex Laboratories Ltd?
Gennex Laboratories Ltd revenue growth is 41.6% for FY-2025, which is above its 5-year CAGR of 11.2%, indicating faster growth.
Q.1 Which industry/sub-sector does Gennex Laboratories Ltd belong to?
Gennex Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.1 Promoter shareholding and pledge status of Gennex Laboratories Ltd?
Promoters hold 23.63% of the Gennex Laboratories Ltd, with 17.42% of their stake pledged, indicating high pledge risk.
Q.1 Revenue growth of Gennex Laboratories Ltd vs industry peers?
Gennex Laboratories Ltd revenue CAGR is 11.20%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

DeciZen - make an informed investing decision on Gennex Lab

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Gennex Laboratories stock performance

Key Ratios
mw4me loader

Is Gennex Laboratories Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gennex Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 11.8%11.6%6.3%10.5%8.3%13.2%11.8%10.7%12.5%10.3%-
Value Creation
Index
-0.2-0.2-0.6-0.3-0.4-0.1-0.2-0.2-0.1-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 38.641.943.855.855.659.761.265.166.894.6106
Sales YoY Gr.-8.7%4.5%27.5%-0.3%7.3%2.6%6.4%2.6%41.6%-
Adj EPS 0.20.20.10.20.10.30.30.20.50.60.6
YoY Gr.-16.7%-71.4%183.3%-29.4%158.3%-9.7%-14.3%112.5%21.6%-
BVPS (₹) 2.12.32.42.62.733.34.57.37.98.9
Adj Net
Profit
2.42.70.92.21.64.13.74.211.71415
Cash Flow from Ops. 3.4-0.13.21.9-1.7-1.46.6-14.5-33.4-9.5-
Debt/CF from Ops. 0.7-36.20.82.4-3-5.11.5-0.2-0.1-0.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.5%11.2%15.6%41.6%
Adj EPS 14.7%38.9%30.3%21.6%
BVPS15.6%23.9%33.3%8.4%
Share Price 2.8% 10.3% 16.9% -23.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
8.79.22.76.74.710.78.76.99.47.97.2
Op. Profit
Mgn %
10.910.95.27.25.8118.8718.610.914.8
Net Profit
Mgn %
6.16.5242.96.866.517.514.813.7
Debt to
Equity
0.10.10.10.10.10.20.2000-
Working Cap
Days
160185203161184204213249436435360
Cash Conv.
Cycle
610215332543705959292

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials

Standalone Consolidated
TTM EPS (₹) 0.6 0.7
TTM Sales (₹ Cr.) 106 152
BVPS (₹) 8.9 9
Reserves (₹ Cr.) 191 195
P/BV 1.13 1.11
PE 16.59 13.78
From the Market
52 Week Low / High (₹) 7.05 / 17.25
All Time Low / High (₹) 0.22 / 29.00
Market Cap (₹ Cr.) 243
Equity (₹ Cr.) 24.3
Face Value (₹) 1
Industry PE 43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.0023.8721.7917.4317.4317.42
* Pledged shares as % of Promoter's holding (%)

Valuation of Gennex Lab - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales39424456566061656795
Operating Expenses + 34374252525356615484
Manufacturing Costs5568866865
Material Costs23242733343638403866
Employee Cost 4566777866
Other Costs 3445444546
Operating Profit 452437551210
Operating Profit Margin (%) 10.9%10.8%5.0%7.2%5.8%11.0%8.8%7.0%18.6%10.9%
Other Income + 0011111349
Exceptional Items -00000-0000-0
Interest 1111111112
Depreciation 1111111111
Profit Before Tax 331335561517
Tax 1011111133
Profit After Tax 231224451214
PAT Margin (%) 6.1%6.5%1.9%4.0%3.3%6.8%6.4%7.0%17.7%14.8%
Adjusted EPS (₹)0.20.20.10.20.10.30.30.30.50.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 2831323436404479165179
Share Capital 13131313131313182323
Reserves 1618192123273161142156
Debt +24355710236
Long Term Debt0000000124
Short Term Debt24255710111
Minority Interest0000000000
Trade Payables7912886861411
Others Liabilities 454586682323
Total Liabilities 4249505257596896205218

Fixed Assets

Net Fixed Assets +15161616151414151620
Gross Block27282930303031333439
Accumulated Depreciation12121314151617171819
CWIP 0000000013
Investments 7777777888
Inventories3325758151625
Trade Receivables7101010681191412
Cash Equivalents flag 1113118146156
Others Assets 8131410212420348996
Total Assets 4249505257596896205218

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 3-032-2-17-14-33-10
PBT 331335561517
Adjustment 1222223-1-2-6
Changes in Working Capital -1-41-3-6-7-0-20-45-21
Tax Paid -0-1-1-0-0-2-10-10
Cash Flow From Investing Activity + -1-1-1-1-0-0-1-113
Capex -1-1-1-1-0-0-0-2-3-6
Net Investments 0000000-100
Others 000000-1348
Cash Flow From Financing Activity + -21-21-02221792
Net Proceeds from Shares 000000030800
Net Proceeds from Borrowing 000-0-0-0-0103
Interest Paid -1-1-1-1-1-1-1-1-1-2
Dividend Paid 0000000000
Others -12-22023-9-00
Net Cash Flow 0-002-207647-5

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)8.699.142.676.755.3210.669.357.439.688.16
ROCE (%)11.7811.616.3110.498.3213.1811.7810.712.510.25
Asset Turnover Ratio10.960.951.171.11.11.030.870.490.5
PAT to CFO Conversion(x)1.5-031-1-0.251.75-2.8-2.75-0.71
Working Capital Days
Receivable Days59.5072.4080.1063.5050.804053.1051.5055.2044.20
Inventory Days19.1024.5020.2023.3038.9035.7035.7058.1076.5070.60
Payable Days111.30125.90147.60113.4088.4071.9065.6065.109969.20

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gennex Laboratories Ltd FAQs

The current trading price of Gennex Lab on 30-Apr-2026 16:59 is ₹9.99.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of Gennex Lab stood at ₹242.7 Cr

The latest P/E ratio of Gennex Lab as of 29-Apr-2026 is 16.59.

The latest P/B ratio of Gennex Lab as of 29-Apr-2026 is 1.13.

The 52-week high of Gennex Lab is ₹17.25 and the 52-week low is ₹7.05.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gennex Lab is ₹106 ( Cr.) .

About Gennex Laboratories Ltd

Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.

The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.

The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.

Products of the company:

  • Guaiphenesin
  • Methocarbamol
  • Fluconazole
  • Phenazopyridine

Certification:

  • Gennex Laboratories is an ISO 9001: 2008 approved company and obtained GMP Certification from the Central Drug Authority.
  • The company is also planning for ISO 14001: 2002 certification and OHSHAS 18000 to ensure its products are more widely accepted in the international market.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×